Microvascular outcomes in type 2 diabetes Reply

被引：0
|
作者：
Zoungas, Sophia [1 ,2 ]
Gerstein, Hertzel C. [3 ,4 ,5 ]
Holman, Rury R. [6 ]
Reaven, Peter [7 ]
Woodward, Mark [1 ,8 ,9 ,10 ]
Arima, Hisatomi [1 ,11 ]
Coleman, Ruth L. [6 ]
Chalmers, John [1 ]
机构：
[1] Univ Sydney, George Inst Global Hlth, Sydney, NSW 2050, Australia
[2] Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Vic, Australia
[3] McMaster Univ, Dept Med, Hamilton, ON, Canada
[4] McMaster Univ, Populat Hlth Res Inst, Hamilton, ON, Canada
[5] Hamilton Hlth Sci, Hamilton, ON, Canada
[6] Univ Oxford, Oxford Ctr Diabet Endocrinol & Metab, Diabet Trials Unit, Oxford, England
[7] Phoenix VA Hlth Care Syst, Phoenix, AZ USA
[8] Univ Oxford, George Inst Global Hlth, Oxford, England
[9] Johns Hopkins Univ, Dept Epidemiol, Baltimore, MD USA
[10] Ann Arbor VA Hlth Care Syst, Ann Arbor, MI USA
[11] Fukuoka Univ, Dept Prevent Med & Publ Hlth, Fukuoka, Japan
来源：
LANCET DIABETES & ENDOCRINOLOGY | 2017年 / 5卷 / 08期
关键词：
D O I：
10.1016/S2213-8587(17)30185-7
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：580 / 580
页数：1
相关论文
共 50 条
  • [1] Microvascular outcomes in type 2 diabetes
    Stehouwer, Coen D. A.
    van Sloten, Thomas T.
    LANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (08): : 579 - 579
  • [2] Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes
    Nathan, David M.
    GRADE Study Res Grp
    Lachin, John M.
    Bebu, Ionut
    Burch, Henry B.
    Buse, John B.
    Cherrington, Andrea L.
    Fortmann, Stephen P.
    Green, Jennifer B.
    Kahn, Steven E.
    Kirkman, M. Sue
    Krause-Steinrauf, Heidi
    Larkin, Mary E.
    Phillips, Lawrence S.
    Pop-Busui, Rodica
    Steffes, Michael
    Tiktin, Margaret
    Tripputi, Mark
    Wexle, Deborah J.
    Younes, Naji
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (12): : 1075 - 1088
  • [3] Liraglutide and Renal Outcomes in Type 2 Diabetes REPLY
    Mann, Johannes F. E.
    Orsted, David D.
    Buse, John B.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (22): : 2197 - 2198
  • [4] Thiazolidinediones and cardiovascular outcomes in type 2 diabetes Reply
    Singh, S.
    Furberg, C. D.
    HEART, 2009, 95 (04) : 332 - 332
  • [5] Microvascular disease and cardiovascular outcomes among individuals with type 2 diabetes
    Kaze, Arnaud D.
    Santhanam, Prasanna
    Erqou, Sebhat
    Bertoni, Alain G.
    Ahima, Rexford S.
    Echouffo-Tcheugui, Justin B.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2021, 176
  • [6] Oral Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes reply
    Husain, Mansoor
    Donsmark, Morten
    Bain, Stephen C.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (21): : 2076 - 2077
  • [7] Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes REPLY
    Zinman, Bernard
    Lachin, John M.
    Inzucchi, Silvio E.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (11): : 1094 - 1094
  • [8] Microvascular disease in diabetes and severe COVID-19 outcomes Reply
    Colhoun, Helen M.
    McGurnaghan, Stuart J.
    McKeigue, Paul M.
    LANCET DIABETES & ENDOCRINOLOGY, 2021, 9 (04): : 201 - 201
  • [9] Finerenone and Chronic Kidney Disease Outcomes in Type 2 Diabetes Reply
    Bakris, George L.
    Agarwal, Rajiv
    Filippatos, Gerasimos
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (11):
  • [10] Impact of Pregnancy on Microvascular and Cardiac Outcomes in Youth-Onset Type 2 Diabetes
    Tryggestad, Jeanie B.
    Kelsey, Megan M.
    Arslanian, Silva A.
    Chernausek, Steven
    Drews, Kimberly
    Escaname, Elia N.
    Geffner, Mitchell
    Isganaitis, Elvira M.
    DIABETES, 2022, 71
12345